XML 63 R12.htm IDEA: XBRL DOCUMENT
v3.22.2

Goodwill and Intangible Assets | 6 Months Ended
--- | ---
Jul. 02, 2022
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | GOODWILL AND INTANGIBLE ASSETS Goodwill Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
|  | December 31, 2021 |  |  |  | Business acquisitions |  |  |  |  |  |  |  | Currency translation adjustments |  | July 2, 2022
CSCA(1) |  | $ | 1,902.4 |  |  |  |  | $ | 106.1 |  |  |  |  |  |  |  |  | $ | (1.6) |  |  | $ | 2,006.9 |
CSCI(2) |  | 1,097.0 |  |  |  |  | 510.1 |  |  |  |  |  |  |  |  | (99.1) |  |  | 1,508.0 |
Total goodwill |  | $ | 2,999.4 |  |  |  |  | $ | 616.2 |  |  |  |  |  |  |  |  | $ | (100.7) |  |  | $ | 3,514.9 |
(1) We had no accumulated goodwill impairments as of July 2, 2022 and $6.1 million as of December 31, 2021. (2) We had accumulated goodwill impairments of $878.4 million as of July 2, 2022 and as of December 31, 2021. Intangible Assets Intangible assets and related accumulated amortization consisted of the following (in millions):
| July 2, 2022 |  | December 31, 2021 |  |
| Gross |  | Accumulated Amortization |  | Gross |  | Accumulated Amortization |  |  |  |
Indefinite-lived intangibles: |  |  |  |  |  |  |  |  |  |  |
Trademarks, trade names, and brands | $ | 3.2 |  |  | $ | — |  |  | $ | 3.5 |  |  | $ | — |  |  |  |  |
In-process research and development | 64.4 |  |  | — |  |  | 1.8 |  |  | — |  |  |  |  |
Total indefinite-lived intangibles | $ | 67.6 |  |  | $ | — |  |  | $ | 5.3 |  |  | $ | — |  |  |  |  |
Definite-lived intangibles: |  |  |  |  |  |  |  |  |  |  |
Distribution and license agreements and supply agreements | $ | 80.1 |  |  | $ | 55.8 |  |  | $ | 73.2 |  |  | $ | 56.9 |  |  |  |  |
Developed product technology, formulations, and product rights | 464.7 |  |  | 198.0 |  |  | 300.2 |  |  | 191.4 |  |  |  |  |
Customer relationships and distribution networks | 1,788.8 |  |  | 883.4 |  |  | 1,820.7 |  |  | 887.8 |  |  |  |  |
Trademarks, trade names, and brands | 2,433.5 |  |  | 407.2 |  |  | 1,482.3 |  |  | 394.2 |  |  |  |  |
Non-compete agreements | 2.1 |  |  | 2.1 |  |  | 2.1 |  |  | 2.1 |  |  |  |  |
Total definite-lived intangibles | $ | 4,769.2 |  |  | $ | 1,546.5 |  |  | $ | 3,678.5 |  |  | $ | 1,532.4 |  |  |  |  |
Total intangible assets | $ | 4,836.8 |  |  | $ | 1,546.5 |  |  | $ | 3,683.8 |  |  | $ | 1,532.4 |  |  |  |  |
We recorded amortization expense of $62.4 million and $110.9 million for the three and six months ended July 2, 2022, respectively, and $53.4 million and $106.6 million for the three and six months ended July 3, 2021, respectively. On March 17, 2022, we announced that we received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg). The approval triggered a $10.0 million milestone payment to the licensor, which was made in the second quarter of 2022 and capitalized as a definite-lived intangible asset.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration